-
Innovative blood test to diagnose Alzheimer's disease was recognized as a breakthrough medical device by the FDA
Time of Update: 2021-11-05
On October 12, 2021, Quanterix announced that its blood test Simoa phospho-Tau 181 (pTau-181) has been granted a breakthrough medical device designation by the US FDA to assist in the diagnosis of Alzheimer's disease (AD) .
-
Biocytometer and Envigo jointly promote the sale of severe immunodeficiency B-NDG mouse models
Time of Update: 2021-11-05
The two parties will work together to promote the extensive application of severe immunodeficiency B-NDG mouse models in related research fields .
For more information, please visit EnvigoEnvigo (Envigo RMS LLC) provides a wide range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations .
-
EbioMedicine: Axitinib may effectively reverse the pathological manifestations of Alzheimer's disease
Time of Update: 2021-11-05
Recently, in a research report titled "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics" published in the international journal EbioMedicine, scientists from the University of British Columbia and other institutions found through research that A drug commonly used to treat cancer may help restore memory and cognitive functions in mice that show symptoms of Alzheimer's disease .
-
This disease affects approximately 280 million people worldwide. RNAi therapy provides new treatment ideas
Time of Update: 2021-11-05
Reference materials:[1] Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder.
-
Bicyclic peptide accurately delivers cytotoxic drugs to treat bladder cancer and ovarian cancer, clinical results are positive
Time of Update: 2021-11-05
Bicycle Therapeutics today announced that two new-generation bicyclic peptide-conjugated toxins have shown positive anti-cancer activity in phase 1 clinical trials .
Among them, the bicyclic peptide-conjugated toxin BT5528 targeting EphA2 allowed two patients with urothelial cancer to obtain partial remission, reaching 80% disease control rate in ovarian cancer patients .
-
Strength target B7-H3: Immunity rookies gradually reveal their edge
Time of Update: 2021-11-05
Preclinical data of ebrolizumab (MGA271) (Reference [13])In clinical studies, according to the data published at the 2018 Annual Meeting of the Society for Cancer Immunotherapy (SITC), the objective response rate (ORR) of ebrolizumab combined with PD-1 monoclonal antibody in the treatment of SCCHN patients reached 33.
-
"Nature" sub-issues sequenced somatic cells, embryos, and sperm to find important genes
Time of Update: 2021-11-05
Studies have reported that in some somatic cells of cancer patients, there are acquired heterozygous missense mutations in the POLE or POLD1 exonuclease domain .
Recently, "Nature-Genetics" published online a collaborative study titled "Increased somatic mutation burdens in normal human cells due to defective DNA polymerases" by Michael R.
-
The Lancet: New changes in clinical trials of lung cancer drugs in China after 15 years
Time of Update: 2021-11-05
Figure 3: All clinical trials of anti-lung cancer drugs (including IND and IIT) in various research phases in China from 2005 to 2020Among the four different stages (I-IV), the growth from 2013 to 2020 is the largest in period I, followed by periods IV, III, and II, with average annual growth rates of 38.
-
Blockbuster PD-L1 inhibitor is approved by FDA to treat early lung cancer and reduce the risk of recurrence by 34%
Time of Update: 2021-11-05
On October 16, Roche announced that the US FDA has approved its blockbuster PD-L1 inhibitor Tecentriq (atezolizumab) as an adjuvant therapy to treat stage II-IIIA non-small cell lung cancer (NSCLC) after surgery and platinum-containing chemotherapy.
Retrieved October 15, 2021, from https:// 2315143/0/en/US-FDA-approves-Roche-s-Tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer.
-
De Nuo Electrophysiology introduces Navik 3D three-dimensional mapping system to build a new ecology for treatment of atrial fibrillation
Time of Update: 2021-11-05
This investment and cooperation aims to introduce APN Health’s core product, Navik 3D™ imaging and navigation system, into the Greater China market, in conjunction with the CardioPulse™ pulse ablation product independently developed by De Nuo Electrophysiology, to isolate and isolate the pulmonary veins of paroxysmal atrial fibrillation.
-
Unique support of gastric acid pump
Time of Update: 2021-11-05
Author: Kazuhiro Abe, Nagoya UniversityResearchers at Nagoya University and their colleagues have a better understanding of the molecular mechanism of a key protein that makes the stomach acidic .
"This gastric protein pumps acidic ions to strengthen our stomach, which is important for digestion, but sometimes causes ulcers .
-
Merck's MET inhibitor Tepmetko is approved by the UK MHRA for the treatment of NSCLC patients
Time of Update: 2021-11-05
CompilationFan DongdongA few days ago, the British Medicines and Healthcare Products Regulatory Agency (MHRA) announced the conditional approval of Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer (NSCLC) patients .
-
Researchers have discovered a new mechanism that regulates the spread of breast cancer
Time of Update: 2021-11-04
The research team of Professor Johanna Ivaska of the University of Turku in Finland has discovered a new mechanism, that is, highly aggressive triple-negative breast cancer cells use integrin circulation and in the tissues Migration .
-
Alzheimer's disease and COVID-19 have a common genetic risk factor
Time of Update: 2021-11-04
OAS1 activity changes with age, so further research on gene networks will help to understand why older people are more susceptible to Alzheimer's disease, Covid-19, and other related diseases .
-
Junk DNA plays a vital role in mammalian development
Time of Update: 2021-11-04
Wild mice use this transposon promoter called MT2B2 to initiate the transcription of the gene Cdk2ap1 in early embryos to produce a short protein "isoform" that increases cell proliferation in fertilized embryos and accelerates its growth.
-
Clinical trial found that interferon does not help hospitalized adults with new coronary pneumonia
Time of Update: 2021-11-04
In this study, Remdesivir is still used as an active control because the first iteration of the ACTT trial found that antiviral drugs are better than placebo in reducing the recovery time of COVID-19 hospitalized patients .
-
Meningitis immunotherapy without antibiotics
Time of Update: 2021-11-04
Now, in a new study on mice, researchers at the University of Copenhagen and Lund University are able to use the body’s own immune cells to kill bacterial meningitis infections .
-
PNAS: A new technology that can detect the health of algae crops
Time of Update: 2021-11-04
Image: A new technology developed by the University of California, San Diego uses chemical ionization mass spectrometry to alert algae growers when volatile gas characteristics change, allowing them to harvest algae crops when they are attacked by contaminating organisms .
-
Science fills the gap: Linking genes and diseases through proteins
Time of Update: 2021-11-04
By linking these disease-related DNA variations with the abundance or function of the encoded protein, the team provided strong evidence of gene involvement and identified a new mechanism for protein-mediated genetic risk of disease .
-
Newly discovered fibromuscular dysplasia gene
Time of Update: 2021-11-04
"We used to think that hand-foot-mouth disease is a rare disease, but the current estimate is that it may affect more than 3% of the population," said the article's second and co-corresponding author Sandra Jean Ganesh, MD, Internal Medicine Associate Professor of Medicine and Human Genetics and Cardiologist at the University of Michigan Health Frankel Cardiovascular Center .
